Advertisement

Low-dose cyclosporine for active lupus nephritis: a dose titration approach

  • Kittiwan SumethkulEmail author
  • Tasanee Kitumnuaypong
  • Sungchai Angthararak
  • Warangkana Pichaiwong
Original Article
  • 66 Downloads

Abstract

Objective

Achievement of complete renal remission (CR) is an important goal in lupus nephritis (LN) treatment. The use of cyclosporine (CsA) for active LN has been challenged because of variations in CsA doses and reports of adverse reactions (AR).

Method

A cohort of 62 patients with active LN (induction-resistant LN and flared LN) who were treated with CsA was evaluated. CsA was started at 50 mg/day and titrated up 25 mg/day every 2–4 weeks until CR was achieved or until treatment termination because of AR.

Results

The range of CsA dosage was 50–200 mg/day, and mean CsA dose was 102.8 ± 50.43 mg/day (1.73 ± 0.91 mg/kg/day). CsA plus mycophenolate mofetil and prednisolone was administered to 35.5% of patients, while the other 64.5% were treated with CsA and prednisolone. 90.32% had achieved CR and 4.84% had partial remission after 12 months of treatment. UPCR (urinary protein:creatinine ratio) decreased significantly in both groups (2.58 ± 3.37 to 0.36 ± 0.71 and 2.32 ± 1.45 to 0.29 ± 0.24 respectively) (P < 0.001). Non-renal activity including arthritis, alopecia, hematologic and cutaneous conditions improved in all patients. Patients whose prednisolone dose were increase received higher doses of prednisolone at baseline than patients who had stable prednisolone dose, but after 12 months the difference in dosage was insignificant (p = 0.58).

Conclusion

Patients with active LN can be effectively treated with low dose CsA, and the dose titration approach can lead to 90.32% CR with low AR rates. No difference in clinical response was observed among patients who received CsA plus prednisolone or CsA plus MMF and prednisolone.

Keywords

Adverse reaction Cyclosporine Flared Induction resistant Lupus nephritis Multitarget therapy 

Notes

Compliance with ethical standards

The study was approved by the ethics committee of the investigating hospital.

Disclosure

None.

References

  1. 1.
    Mak A, Cheung MW, Chiew HJ, Liu Y, Ho RC (2012) Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 41(6):830–839CrossRefGoogle Scholar
  2. 2.
    Mok CC, Kwok RC, Yip PS (2013) Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 65(8):2154–2160CrossRefGoogle Scholar
  3. 3.
    Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71(11):1771–1782CrossRefGoogle Scholar
  4. 4.
    Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797–808CrossRefGoogle Scholar
  5. 5.
    Grootscholten C, Berden JH (2006) Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 21(6):1465–1469CrossRefGoogle Scholar
  6. 6.
    Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68(6):1432–1441CrossRefGoogle Scholar
  7. 7.
    Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ (2008) Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3(1):46–53CrossRefGoogle Scholar
  8. 8.
    Mok CC (2016) Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant 31(10):1561–1566CrossRefGoogle Scholar
  9. 9.
    Xiong W, Lahita RG (2014) Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10(2):97–107CrossRefGoogle Scholar
  10. 10.
    Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR, Sumethkul V, Shen N, Chen SL, Chan TM (2014) Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) 19(1):11–20CrossRefGoogle Scholar
  11. 11.
    Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y (2010) Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 37(3):512–520CrossRefGoogle Scholar
  12. 12.
    Chighizola CB, Ong VH, Meroni PL (2017) The use of cyclosporine a in rheumatology: a 2016 comprehensive review. Clin Rev Allergy Immunol 52(3):401–423CrossRefGoogle Scholar
  13. 13.
    Moroni G, Doria A, Ponticelli C (2009) Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 24(1):15–20CrossRefGoogle Scholar
  14. 14.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefGoogle Scholar
  15. 15.
    Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS (2004) The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 31(10):1934–1940Google Scholar
  16. 16.
    Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J (1994) Effect of low-dose cyclosporin a on systemic lupus erythematosus disease activity. Arthritis Rheum 37(4):551–558CrossRefGoogle Scholar
  17. 17.
    Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L (1997) Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 40(1):27–35CrossRefGoogle Scholar
  18. 18.
    Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova J, Stejskalova A, Tegzova D (1998) Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 7(1):29–36CrossRefGoogle Scholar
  19. 19.
    Borigini MJ, Paulus HE (1995) Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Baillieres Clin Rheumatol 9(4):689–710CrossRefGoogle Scholar
  20. 20.
    Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, Wakita T, Kato N, Shimotohno K (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80(9):4510–4520CrossRefGoogle Scholar
  21. 21.
    Biggioggero M, Borghi MO, Gerosa M, Trespidi L, Cimaz R, Meroni PI (2007) Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus 16(8):651–656CrossRefGoogle Scholar
  22. 22.
    Fernandez Nieto M, Jayne DR (2016) Con: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant 31(10):1567–1571CrossRefGoogle Scholar
  23. 23.
    Griffiths B, Emery P (2001) The treatment of lupus with cyclosporin A. Lupus 10(3):165–170CrossRefGoogle Scholar
  24. 24.
    Ryan C, Amor KT, Menter A (2010) The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 63(6):949–997CrossRefGoogle Scholar
  25. 25.
    Ogawa H, Kameda H, Amano K, Takeuchi T (2010) Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19(2):162–169CrossRefGoogle Scholar
  26. 26.
    Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, Medina JA, Ugarte A, Erdozain JG, Ruiz-Irastorza G (2018) Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res 70(4):582–591CrossRefGoogle Scholar
  27. 27.
    Radhakrishnan J, Kunis CL, D'Agati V, Appel GB (1994) Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42(3):147–154Google Scholar
  28. 28.
    Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2000) Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9(4):241–251CrossRefGoogle Scholar
  29. 29.
    Austin HA 3rd, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20(4):901–911CrossRefGoogle Scholar
  30. 30.
    Maes BD, Vanrenterghem YF (2004) Cyclosporine: advantages versus disadvantages vis-a-vis tacrolimus. Transplant Proc 36(2 Suppl):40S–49SCrossRefGoogle Scholar
  31. 31.
    Jesus D, Rodrigues M, da Silva JAP, Ines L (2018) Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus 27(8):1358–1362CrossRefGoogle Scholar
  32. 32.
    Kasitanon N, Boripatkosol P, Louthrenoo W (2018) Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis 21(1):200–207CrossRefGoogle Scholar
  33. 33.
    Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD (2004) Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78(4):557–565CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  • Kittiwan Sumethkul
    • 1
    Email author
  • Tasanee Kitumnuaypong
    • 1
  • Sungchai Angthararak
    • 1
  • Warangkana Pichaiwong
    • 2
  1. 1.Rheumatology Unit, Department of Medicine, Rajavithi HospitalCollege of Medicine, Rangsit UniversityBangkokThailand
  2. 2.Nephrology Unit, Department of Medicine, Rajavithi HospitalCollege of Medicine, Rangsit UniversityBangkokThailand

Personalised recommendations